Literature DB >> 17631071

Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial).

Steven P Marso1, Todd Miller, Barry D Rutherford, Raymond J Gibbons, Mansoor Qureshi, Anna Kalynych, Mark Turco, Heinz P Schultheiss, Roxana Mehran, Mitchell W Krucoff, Alexandra J Lansky, Gregg W Stone.   

Abstract

Diabetes mellitus is strongly associated with increased cardiovascular morbidity and mortality in patients with ST-segment elevation myocardial infarction. It is unknown whether myocardial perfusion is decreased in diabetic compared with nondiabetic patients after primary percutaneous coronary intervention (PCI), which may contribute to their worse prognosis. We compared myocardial perfusion and infarct sizes between diabetic and nondiabetic patients undergoing PCI for acute ST-segment elevation myocardial infarction in the EMERALD trial. EMERALD was a prospective, randomized, multicenter study evaluating distal embolic protection during primary PCI in ST-segment elevation myocardial infarction. End points included final myocardial blush grade, complete ST-segment resolution (STR) 30 minutes after PCI, and final infarct size as determined by technetium-99m single proton emission computed tomography measured between days 5 and 14. Of 501 patients, 62 (12%) had diabetes mellitus. Diabetic patients had impaired myocardial perfusion after PCI as measured by myocardial blush grade 0/1 (34% vs 16%, p = 0.002) and lower rates of complete 30-minute STR (45% vs 65%, p = 0.005). Infarct size (median 20% vs 11%, p = 0.005), development of new onset severe congestive heart failure (12% vs 4%, p = 0.016), and 30-day mortality (10% vs 1%, p <0.0001) were also greater in diabetic patients. After multivariate adjustment, diabetes remained associated with lack of complete STR and mortality at 6 months. Use of distal protection devices did not improve outcomes in diabetic or nondiabetic patients. In conclusion, in patients with ST-segment elevation myocardial infarction undergoing primary PCI, diabetes is independently associated with decreased myocardial reperfusion, larger infarct, development of congestive heart failure, and decreased survival.

Entities:  

Mesh:

Year:  2007        PMID: 17631071     DOI: 10.1016/j.amjcard.2007.02.080

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  37 in total

Review 1.  Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.

Authors:  Louise E See Hoe; Lauren T May; John P Headrick; Jason N Peart
Journal:  Br J Pharmacol       Date:  2016-09-09       Impact factor: 8.739

2.  Elective percutaneous coronary intervention: the relationship between preprocedural blood glucose levels and periprocedural myocardial injury.

Authors:  Mohsen Madani; Keivan Alizadeh; Sepideh Parchami Ghazaee; Abbas Zavarehee; Seifollah Abdi; Farshad Shakerian; Negar Salehi; Ata Firouzi
Journal:  Tex Heart Inst J       Date:  2013

3.  Ameliorative potential of conditioning on ischemia-reperfusion injury in diabetes.

Authors:  Ashish K Rehni; Kunjan R Dave
Journal:  Cond Med       Date:  2018-04-20

4.  Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication.

Authors:  Joseph Wider; Vishnu V R Undyala; Peter Whittaker; James Woods; Xuequn Chen; Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2018-03-09       Impact factor: 17.165

5.  Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart.

Authors:  Romain Harmancey; Hernan G Vasquez; Patrick H Guthrie; Heinrich Taegtmeyer
Journal:  FASEB J       Date:  2013-06-27       Impact factor: 5.191

Review 6.  Ischemic conditioning: the challenge of protecting the diabetic heart.

Authors:  Joseph Wider; Karin Przyklenk
Journal:  Cardiovasc Diagn Ther       Date:  2014-10

7.  Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES.

Authors:  Giuseppe De Luca; Rosario Sauro; Attilio Varricchio; Michele Capasso; Tonino Lanzillo; Fiore Manganelli; Ciro Mariello; Francesco Siano; Giannignazio Carbone; Maria Rosaria Pagliuca; Giuseppe Rosato; Emilio Di Lorenzo
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

8.  The prognostic significance of serum glucose levels after the onset of ventricular arrhythmia on in-hospital mortality of patients with acute coronary syndrome.

Authors:  Vassilios N Nicolaou; John E Papadakis; Christina Chrysohoou; Demosthenes B Panagiotakos; Xenofon Krinos; Panagiotis D Skoufas; Christodoulos Stefanadis
Journal:  Rev Diabet Stud       Date:  2008-05-10

9.  Benefits of pharmacological facilitation with glycoprotein IIb-IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT cooperation.

Authors:  Giuseppe De Luca; C Michael Gibson; Francesco Bellandi; Sabina Murphy; Mauro Maioli; Marko Noc; Uwe Zeymer; Dariusz Dudek; Hans-Richard Arntz; Simona Zorman; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Mariann Gyongyosi; Kurt Huber; Arnoud W J Van't Hof
Journal:  J Thromb Thrombolysis       Date:  2008-11-22       Impact factor: 2.300

10.  Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling.

Authors:  Hannah J Whittington; Idris Harding; Clemency I M Stephenson; Robert Bell; Derek J Hausenloy; Mihaela M Mocanu; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2013-05-30       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.